{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T08:19:37Z","timestamp":1788941977332,"version":"build-2803163510"},"reference-count":68,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,1,17]],"date-time":"2025-01-17T00:00:00Z","timestamp":1737072000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:sec><jats:title>Aims<\/jats:title><jats:p>This study aims to evaluate the efficacy and safety of tripterygium glycosides combined with angiotensin-converting enzyme inhibitors\/angiotensin receptor blockers (ACEI\/ARBs) in treating Diabetic nephropathy and provide high-level evidence to support its standardized application.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Literatures were retrieved from PubMed, Web of Science, EMBASE, Cochrane Library, CNKI, Wanfang and VIP databases, the search time frame was defined as from the time of establishment to April 2023. This study only included randomized controlled trials of tripterygium glycosides combined with ACEI\/ARB in the treatment of diabetic nephropathy, and the final included studies were identified according to the inclusion and exclusion criteria, and meta-analysis of data was performed using RevMan 5.3 software.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>A total of 44 RCTs with 3537 DN patients were included in the study. Compared with the control group, tripterygium glycosides combined with ACEI\/ARB significantly reducing 24\u00a0h-UTP (24\u00a0h urine total protein) [SMD = \u22121.46, 95% CI (\u22121.70, \u22121.23), P &amp;lt; 0.00001], increasing effective rate [RR = 1.23, 95% CI (1.17,1.29), P &amp;lt; 0.00001], elevating serum albumin [SMD = 0.85, 95% CI (0.69, 1.02), P &amp;lt; 0.00001], improving serum creatinine [SMD = \u22120.35, 95% CI (\u22120.59, \u22120.11), P = 0.004], with no difference in BUN (blood urea nitrogen) [SMD = \u22120.17, 95% CI (\u22120.48,0.13), P = 0.27], the adverse reactions rate was higher than those of the control group [RR = 1.96, 95%CI (1.43, 2.68), P &amp;lt; 0.0001].<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>This study showed that the combination of tripterygium glycosides and ACEI\/ARB was more effective than ACEI\/ARB alone. However, the side effects of the combined treatment group were higher than those of the control group, especially liver function damage, which also suggested that its safety in the treatment of diabetic nephropathy was worth considering. Therefore, although tripterygium glycosides provided a choice for the clinical treatment of diabetic nephropathy, its side effects limited its clinical application. In future studies, we need to further optimize tripterygium glycosides and reduce its side effects to ensure the safety of clinical application.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fphar.2024.1493590","type":"journal-article","created":{"date-parts":[[2025,1,17]],"date-time":"2025-01-17T06:51:01Z","timestamp":1737096661000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":7,"title":["Efficacy and safety of tripterygium glycosides combined with ACEI\/ARB on diabetic nephropathy: a meta-analysis"],"prefix":"10.3389","volume":"15","author":[{"given":"Zhuan\u2019E.","family":"Yao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pengbo","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qinjuan","family":"Fu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiong","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haojian","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peng","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,1,17]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"884","DOI":"10.1001\/jama.2015.10081","article-title":"Effect of finerenone on albuminuria in patients with diabetic nephropathy: a randomized clinical trial","volume":"314","author":"Bakris","year":"2015"},{"key":"B2","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1056\/NEJMoa2030186","article-title":"Sotagliflozin in patients with diabetes and chronic kidney disease","volume":"14","author":"Bhatt","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"B3","first-page":"112","article-title":"ARB combined with tripterygium glycosides regimen for treatment of patients with diabetic nephropathy","volume":"16","author":"Cai","year":"2012","journal-title":"J. Clin. Med. Pract."},{"key":"B4","doi-asserted-by":"publisher","first-page":"156","DOI":"10.14163\/j.cnki.11-5547\/r.2010.30.120","article-title":"Effect of valsartan dispersive tablets combined with Tripterygium Glycosides on diabetic nephropathy albuminuria","volume":"5","author":"Cao","year":"2010","journal-title":"China Prac. Med."},{"key":"B5","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1016\/j.jfma.2019.11.001","article-title":"Evaluation of the efficacy and safety of TWHF in diabetic nephropathy patients with overt proteinuria and normal eGFR","volume":"19","author":"Chang","year":"2020","journal-title":"J. Formos. Med. Assoc."},{"key":"B6","doi-asserted-by":"publisher","first-page":"1149","DOI":"10.3760\/cma.j.issn.1008-6315.2012.11.010","article-title":"Effect of irbesartan and triptolide combination on the level of urine protein in patients with diabetic nephropathy at high altitude area","volume":"28","author":"Chen","year":"2012","journal-title":"Clin. Med. China"},{"key":"B7","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1186\/s12906-019-2491-y","article-title":"Traditional Chinese medicine use is associated with lower end-stage renal disease and mortality rates among patients with diabetic nephropathy: a population-based cohort study","volume":"19","author":"Chen","year":"2019","journal-title":"BMC Complement. Altern. Med."},{"key":"B8","first-page":"106","article-title":"Clinical observation of Tripterygium wilfordii polyglycoside combined with Benazepril on diabetic nephropathy albuminuria","volume":"34","author":"Chen","year":"2013","journal-title":"Shaanxi J Traditional Chin. Med."},{"key":"B9","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1159\/000506634","article-title":"Diabetic kidney disease: challenges, advances, and opportunities","volume":"6","author":"Chen","year":"2020","journal-title":"Kidney Dis. Basel Switz."},{"key":"B10","doi-asserted-by":"publisher","first-page":"e32504","DOI":"10.1097\/MD.0000000000032504","article-title":"The effect and safety of low-dose tripterygium wilfordii in patients with type 2 diabetic nephropathy: a meta-analysis","volume":"101","author":"Chen","year":"2022","journal-title":"Med."},{"key":"B11","doi-asserted-by":"publisher","first-page":"1646","DOI":"10.1111\/dom.15019","article-title":"Efficacy and safety of sotagliflozin in patients with type 2 diabetes and stage 3 chronic kidney disease","volume":"25","author":"Cherney","year":"2023","journal-title":"Diabetes Obes. Metab."},{"key":"B12","doi-asserted-by":"publisher","first-page":"46","DOI":"10.15887\/j.cnki.13-1389\/r.2013.23.076","article-title":"Clinical observation of Tripterygium wilfordii glycosides on diabetic nephropathy albuminuria","volume":"6","author":"Chi","year":"2013","journal-title":"Chin J Clin. Ration. Drug Use"},{"key":"B13","first-page":"1088","article-title":"Effect of Tripterygium wilfordii polyglycosides combined with Fosinopril on CRP and TNF-\u03b1 in early diabetic nephropathy","volume":"14","author":"Diao","year":"2013","journal-title":"CJITWN"},{"key":"B14","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1186\/1479-5876-11-134","article-title":"Treatment of diabetic nephropathy with tripterygium wilfordii Hook F extract: a prospective, randomized, controlled clinical trial","volume":"31","author":"Ge","year":"2013","journal-title":"J. Transl. Med."},{"key":"B15","doi-asserted-by":"publisher","first-page":"291","DOI":"10.3390\/biomedicines11020291","article-title":"Advances in the pharmacological management of diabetic nephropathy: a 2022 international update","volume":"11","author":"Giglio","year":"2023","journal-title":"Biomed"},{"key":"B16","first-page":"3032","article-title":"Clinical observation of tripterygium glycosides combined with valsartan in treatment of stage I-III diabetic nephropathy","volume":"21","author":"He","year":"2010","journal-title":"Lishizhen Med. Mater Med. Res."},{"key":"B17","doi-asserted-by":"publisher","first-page":"212","DOI":"10.13820\/j.cnki.gdyx.2016.s1.094","article-title":"Effect of Tripterygium wilfordii polyglycoside combined with Benazepril on diabetic nephropathy albuminuria","volume":"37","author":"He","year":"2016","journal-title":"Guangdong Med. J."},{"key":"B18","doi-asserted-by":"publisher","first-page":"109599","DOI":"10.1016\/j.biopha.2019.109599","article-title":"Tripterygium and its extracts for diabetic nephropathy: efficacy and pharmacological mechanisms","volume":"121","author":"Huang","year":"2020","journal-title":"Biomed. Pharmacother."},{"key":"B19","doi-asserted-by":"publisher","first-page":"145+147","DOI":"10.16484\/j.cnki.issn2095-8803.2020.25.093","article-title":"Effect of tripterygium glycosides combined with valsartan on diabetic nephropathy","volume":"7","author":"Jia","year":"2020","journal-title":"Electron. J. Of Pract. Gynecol. Endocrinol."},{"key":"B20","first-page":"115","article-title":"Clinical efficacy of tripterygium glycosides combined with valsartan in the treatment of diabetic nephropathy","volume":"31","author":"Jiang","year":"2018","journal-title":"Med. Equip."},{"key":"B21","first-page":"987","article-title":"Clinical observation of tripterygium glycosides combined with telmisartan in treatment of diabetic nephropathy","volume":"30","author":"Jiang","year":"2015","journal-title":"Drugs Clin."},{"key":"B22","first-page":"86","article-title":"Clinical effect of Tripterygium Glycosides combined with Valsartan in the treatment of patients with stage IV diabetic nephropathy","volume":"27","author":"Jin","year":"2020","journal-title":"China Mod. Med."},{"key":"B23","doi-asserted-by":"publisher","first-page":"9181037","DOI":"10.1155\/2020\/9181037","article-title":"Tripterygium wilfordii Hook F treatment for stage IV diabetic nephropathy: protocol for a prospective, randomized controlled trial","volume":"2020","author":"Lengnan","year":"2020","journal-title":"Biomed. Res. Int."},{"key":"B24","first-page":"31","article-title":"Clinical observation of irbesartan combined with tripterygium glycosides in treatment of type 2 diabetic nephropathy","volume":"36","author":"Li","year":"2014","journal-title":"J. Yichun Univ."},{"key":"B25","first-page":"43","article-title":"Clinical observation of diabetic nephropathy under the treatment of tripterygium glycosides combined with valsartan","volume":"3","author":"Li","year":"2011","journal-title":"Chin. Commun. Dr."},{"key":"B26","doi-asserted-by":"publisher","first-page":"1048","DOI":"10.3969\/j.issn.1671-7171.2015.06.003","article-title":"Effectiveness of tripteryguim wilfordli plus irbesartan in patients with early\u2010to\u2010mid diabetic nephropathy","volume":"32","author":"Li","year":"2015","journal-title":"J. Clin. Res."},{"key":"B27","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1111\/nep.14167","article-title":"Practical considerations for the use of SGLT-2 inhibitors in the Asia-Pacific countries-An expert consensus statement","volume":"28","author":"Liew","year":"2023","journal-title":"Nephrol. Carlt."},{"key":"B28","doi-asserted-by":"publisher","first-page":"173","DOI":"10.16658\/j.cnki.1672-4062.2018.23.173","article-title":"Effect of Tripterygium wilfordii polyglycosides combined with Candesartan on diabetic nephropathy","author":"Lin","year":"2018","journal-title":"Diabetes New World"},{"key":"B29","doi-asserted-by":"publisher","first-page":"747922","DOI":"10.3389\/fmed.2021.747922","article-title":"The active compounds and therapeutic target of tripterygium wilfordii Hook. f. in attenuating proteinuria in diabetic nephropathy: a review","volume":"8","author":"Liu","year":"2021","journal-title":"Front. Med. (Lausanne)"},{"key":"B30","first-page":"56","article-title":"The effect of valsartan combined with Tripterygium wilfordii glycosides on alleviating proteinuria","volume":"11","author":"Liu","year":"2015","journal-title":"J Pract. Diabetology."},{"key":"B31","doi-asserted-by":"publisher","first-page":"1739","DOI":"10.1142\/S0192415X22500744","article-title":"A review of traditional Chinese medicine on treatment of diabetic nephropathy and the involved mechanisms","volume":"50","author":"Liu","year":"2022","journal-title":"Am. J. Chined"},{"key":"B32","doi-asserted-by":"publisher","first-page":"1084448","DOI":"10.3389\/fimmu.2023.1084448","article-title":"T cells and their products in diabetic kidney disease","volume":"14","author":"Liu","year":"2023","journal-title":"Front. Immunol."},{"key":"B33","first-page":"94","article-title":"Application effect of Tripterygium wilfordii polyglycosides combined with valsartan in the treatment of diabetic nephropathy","volume":"11","author":"Lu","year":"2017","journal-title":"World Clin. Med."},{"key":"B34","doi-asserted-by":"publisher","first-page":"649","DOI":"10.3892\/etm.2013.1226","article-title":"Triptolide markedly attenuates albuminuria and podocyte injury in an animal model of diabetic nephropathy","volume":"6","author":"Ma","year":"2013","journal-title":"Exp. Ther. Med."},{"key":"B35","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1007\/s11154-008-9103-3","article-title":"Defining human diabetic nephropathy on the molecular level: integration of transcriptomic profiles with biological knowledge","volume":"9","author":"Martini","year":"2008","journal-title":"Rev. Endocr. Metab. Disord."},{"key":"B36","doi-asserted-by":"publisher","first-page":"2295","DOI":"10.1056\/NEJMoa1811744","article-title":"Canagliflozin and renal outcomes in type 2 diabetes and nephropathy","volume":"380","author":"Perkovic","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"B37","doi-asserted-by":"publisher","first-page":"e33235","DOI":"10.7759\/cureus.33235","article-title":"A narrative review of new treatment options for diabetic nephropathy","volume":"15","author":"Pillai","year":"2023","journal-title":"Cureus"},{"key":"B38","first-page":"5789","article-title":"Analysis of the effect of valsartan dispersible tablets and tripterygium of glycosides in the treatment of 78 patients with diabetic nephropathy proteinuria","volume":"34","author":"Pu","year":"2013","journal-title":"Jilin Med. J."},{"key":"B39","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1161\/CIRCULATIONAHA.121.055459","article-title":"Effect of the glucagon-like peptide-1 receptor agonists semaglutide and liraglutide on kidney outcomes in patients with type 2 diabetes: pooled analysis of SUSTAIN 6 and LEADER","volume":"145","author":"Shaman","year":"2022"},{"key":"B40","doi-asserted-by":"publisher","first-page":"158","DOI":"10.13457\/j.cnki.jncm.2014.06.076","article-title":"Clinical observation of tripterygium glycosides combined with irbesartan in treatment of diabetic nephropathy","volume":"46","author":"Shen","year":"2014","journal-title":"J. New Chin. Med."},{"key":"B41","first-page":"416","article-title":"Effect of triptolide on urinary monocyte chemottractant protein-1 in patients with diabetic nephropathy","volume":"25","author":"Song","year":"2005","journal-title":"Chin. J. Integr. Traditional West. Med."},{"key":"B42","first-page":"154+156","article-title":"Effect of valsartan dispersive tablets and Tripterygium wilfordii glycosides on diabetic nephropathy albuminuria","volume":"22","author":"Song","year":"2014","journal-title":"China Med. Eng."},{"key":"B43","first-page":"32","article-title":"Clinical observation of massive proteinuria of diabetic nephropathy under the treatment of tripterygium glycosides combined with irbesartan","volume":"5","author":"Tan","year":"2010","journal-title":"Natl. Med. Front. China"},{"key":"B44","doi-asserted-by":"publisher","first-page":"592","DOI":"10.3892\/mmr.2021.12231","article-title":"Tripterygium glycoside suppresses epithelial\u2011to\u2011mesenchymal transition of diabetic kidney disease podocytes by targeting autophagy through the mTOR\/Twist1 pathway","volume":"24","author":"Tao","year":"2021","journal-title":"Mol. Med. Rep."},{"key":"B45","doi-asserted-by":"publisher","first-page":"1527","DOI":"10.16766\/j.cnki.issn.1674-4152.2017.09.023","article-title":"Effect of tripterygium wilfordii polyglycoside combined telmisartan on renal function and hemorheology in patients with diabetic nephropathy","volume":"15","author":"Tu","year":"2017","journal-title":"Chin. J. General Pract."},{"key":"B46","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1002\/ptr.5987","article-title":"Efficacy and safety of Tripterygium wilfordii Hook F for CKD in mainland China: a systematic review and meta-analysis","volume":"32","author":"Wang","year":"2018","journal-title":"Phytotherapy Res."},{"key":"B47","first-page":"159","article-title":"Effect of Tripterygium wilfordii glycosides on proteinuria level and renal function in diabetic nephropathy","volume":"31","author":"Wang","year":"2019","journal-title":"Strait Pharm. J."},{"key":"B48","doi-asserted-by":"publisher","first-page":"110","DOI":"10.15912\/j.cnki.gocm.2017.34.088","article-title":"Effect of Tripterygium wilfordii polyglycoside combined with Benazepril in the treatment of diabetic nephropathy proteinuria, 24 h urinary protein content and 24 h urinary microalbumin excretion","volume":"15","author":"Wang","year":"","journal-title":"Guide China Med."},{"key":"B49","doi-asserted-by":"publisher","first-page":"31","DOI":"10.16658\/j.cnki.1672-4062.2016.17.031","article-title":"Clinical effects of tripterygium glycosides combined with valsartan in treatment of diabetic nephropathy","volume":"19","author":"Wang","year":"2016","journal-title":"Diabetes New World"},{"key":"B50","doi-asserted-by":"publisher","first-page":"84","DOI":"10.15887\/j.cnki.13-1389\/r.2012.22.085","article-title":"Clinical observation of proteinuria of type 2 diabetic nephropathy under the treatment of valsartan combined with tripterygium glycosides","volume":"5","author":"Wang","year":"2012","journal-title":"Chin J Clin. Ration. Drug Use"},{"key":"B51","first-page":"51","article-title":"Clinical observation of Tripterygium glycosides combined with benazepril in the treatment of proteinuria on diabetic nephropathy","volume":"15","author":"Wang","year":"","journal-title":"J. China Prescr. Drug"},{"key":"B52","first-page":"45","article-title":"Clinical observation of proteinuria of type 2 diabetic nephropathy under the treatment of tripterygium glycosides combined with telmisartan","volume":"11","author":"Wang","year":"2013","journal-title":"Chin. Med. Mod. Distance Educ. China"},{"key":"B53","first-page":"1173","article-title":"Double dose tripterygium glycosides combined with telmisartan in treatment of 32 cases of early diabetic nephropathy","volume":"29","author":"Wu","year":"2010","journal-title":"Her. Med."},{"key":"B54","first-page":"394","article-title":"Clinical observation of Tripterygium glycosides combined with valsartan in the treatment of diabetic nephropathy with massive albuminuria","volume":"21","author":"Wu","year":"2012","journal-title":"Mod. J. Integr. Traditional Chin. West. Med."},{"key":"B55","doi-asserted-by":"publisher","first-page":"721","DOI":"10.3892\/ijmm.2017.3068","article-title":"Multi-glycoside of Tripterygium wilfordii Hook. f. attenuates glomerulosclerosis in a rat model of diabetic nephropathy by exerting anti-microinflammatory effects without affecting hyperglycemia","volume":"40","author":"Wu","year":"2017","journal-title":"Int. J. Mol. Med."},{"key":"B56","first-page":"753","article-title":"Clinical observation on the effect of Valsartan combined with Tripterygium glycosides in the treatment of diabetic nephropathy stage IV","volume":"18","author":"Wu","year":"2018","journal-title":"Chin. Remedies Clin."},{"key":"B57","doi-asserted-by":"publisher","first-page":"90","DOI":"10.16485\/j.issn.2095-7858.2014.01.038","article-title":"Clinical analysis of Tripterygium wilfordii polyglycoside combined with Benazepril in the treatment of diabetic nephropathy albuminuria","volume":"12","author":"Xu","year":"2014","journal-title":"J. Bethune Med. Sci."},{"key":"B58","first-page":"95","article-title":"Clinical observation on treating diabetic nephropathy during IV period with the tripterygium glycosides tablets","volume":"8","author":"Xu","year":"2016","journal-title":"Clin. J Chin. Med."},{"key":"B59","first-page":"356","article-title":"Effects of tripterygium wilfordii extract on T lymphocytes and urinary microprotein in patients with diabetic nephropathy","volume":"22","author":"Yan","year":"2017","journal-title":"Lingnan J Emerg. Med."},{"key":"B60","doi-asserted-by":"publisher","first-page":"553","DOI":"10.16047\/j.cnki.cn14-1300\/r.2016.07.029","article-title":"Losartan combined with tripterygium glycosides for treatment of patients with stage IV diabetic nephropathy","volume":"25","author":"Yang","year":"2016","journal-title":"Proc. Clin. Med."},{"key":"B61","doi-asserted-by":"publisher","first-page":"134","DOI":"10.14164\/j.cnki.cn11-5581\/r.2018.11.075","article-title":"Effect of Tripterygium wilfordii polyglycoside combined with Benazepril on diabetic nephropathy albuminuria","volume":"12","author":"Yang","year":"2018","journal-title":"Chin. J. Mod. Drug Appl."},{"key":"B62","first-page":"248","article-title":"Tripterygium glycosides tablet for treatment of 66 cases of stage IV diabetic nephropathy","volume":"24","author":"Zhang","year":"2015","journal-title":"China Pharm."},{"key":"B63","first-page":"73","article-title":"Observation of curative effect on type 2 diabetic nephropathy treated with tripterygium glycosides and irbesartan","volume":"9","author":"Zhang","year":"2012","journal-title":"China Med. Her."},{"key":"B64","first-page":"1427","article-title":"Effects of tripterygium wilfordii polyglucoside on expression of Activin A and influence of transdifferentiation in renal tubulointerstitium of rats with diabetic nephropathy","volume":"13","author":"Zhao","year":"2014","journal-title":"Zhonghua Yi Xue Za Zhi"},{"key":"B65","first-page":"811","article-title":"Clinical observation of tripterygium glycosides combined with valsartan in treatment of 46 cases diabetic nephropathy","volume":"12","author":"Zhao","year":"2011","journal-title":"Chin. J. Integr. Tradit. West. Nephrol."},{"key":"B66","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1038\/ki.2008.203","article-title":"Triptolide protects podocytes from puromycin aminonucleoside induced injury in vivo and in vitro","volume":"74","author":"Zheng","year":"2008","journal-title":"Kidney Int."},{"key":"B67","first-page":"94","article-title":"Clinical observation of massive proteinuria of diabetic nephropathy under the treatment of tripterygium glycosides combined with valsartan","volume":"7","author":"Zhou","year":"2013","journal-title":"For All Health"},{"key":"B68","doi-asserted-by":"publisher","first-page":"1266","DOI":"10.3969\/ji.ssn.1000-7377.2017.09.047","article-title":"Clinical observation of 97 patients with tripterygium glycosides in combination with valsartan on diabetic nephropathy","volume":"46","author":"Zhou","year":"2017","journal-title":"Shaanxi Med. J."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2024.1493590\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,17]],"date-time":"2025-01-17T06:51:18Z","timestamp":1737096678000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2024.1493590\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,17]]},"references-count":68,"alternative-id":["10.3389\/fphar.2024.1493590"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2024.1493590","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,17]]},"article-number":"1493590"}}